ReviewMaterials today. Bio2026
Microneedle-based theranostics for melanoma: Advances and outlook.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma represents a highly aggressive malignancy that poses persistent challenges for clinical diagnosis and treatment. Although surgical intervention remains the primary therapeutic approach, the potential risk of postoperative recurrence and surgical complications underscores the critical importance of adjuvant therapies. Microneedles (MNs), as a promising drug delivery device, utilize micron-sized needle arrays to penetrate the skin's stratum corneum, achieving precise drug delivery. Furthermore, MNs can effectively extract biomarkers from interstitial fluid (ISF), holding great potential for early disease screening and point-of-care testing (POCT). This review systematically summarizes the classification and advanced design strategies of MNs, alongside the latest progress in nano-integrated MN platforms for melanoma diagnosis and treatment. The advantages and limitations of novel therapies, as well as the synergistic mechanisms underlying combination treatments, are discussed in detail. Finally, we explore the major challenges in clinical translation, such as large-scale manufacturing and regulatory hurdles, while outlining future directions, including multi-stimuli responsive designs and the integration of Artificial Intelligence (AI) in MN fabrication and application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.